TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03472989

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial extracorporeal shock wave
Description: Patients will receive treatment once a week for 3 weeks. Treatment will be administered by using the rESWT device named Swiss DolorClast (EMS). 2000 impulses are implied via the power hand piece to the area of max tenderness at the insertion of the plantar fascia, with a pressure of 1.5-3 bars depending on what the patient tolerates. The treatments will be given by a trained physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-radial extracorporeal shock wave
Description: Patients will receive the same treatment as the patients in the group receiving real shock waves, but no real shock waves are conducted. The probe is similar in design, sound and shape.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized high-load exercise program
Description: Patients will be instructed to do 2 exercises: Unilateral heel raise and unilateral leg squat three times a week for 12 weeks. The patients will have a total of 8 sessions supervised by a physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will get standardized information as in the other three intervention groups with information on pathogenesis, etiology and prognosis, and they will get custom made foot orthosis
Study: NCT04566913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pontic Shield Technique
Description: • Together the apical and the palatal portions of the root in the esthetic region will be delivered and the buccal part is left for assessment of stability of bucco-palatal dimension of alveolar ridge
Study: NCT01885689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic hematopoietic stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01825798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.
Study: NCT03197168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to reduce self-stigma among people with mental illness
Description: This is a 10-session group intervention (held once a week), each lasting approximately 90 minutes, taking place where the participants receive mental health treatment.~The intervention is informed by the following key areas: (1) recovery perspective of mental health and severe mental disorders; (2) constructivist epistemology approach to learning, using cases and users' experiences; and (3) psychotherapeutic and collective narrative practices, to address internalized problems and challenges shared among the group members, respectively.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Generally, each community mental health center in Chile includes two full-time psychologists, a full-time social worker and half-time occupational therapist, nurse, and psychiatrist. This team mainly offers psychiatric medication, psychotherapy, and psycho-education for users and relatives. They do not offer any specific intervention to tackle stigma among providers.
Study: NCT02932098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge instructions reminders
Description: Week 1, Day 1: Click through each discharge instruction; Week 1, Days 2-7: Click through single list of all discharge instructions.~Participants will receive a reminder of discharge instructions everyday for the first week post-discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prompts to report symptoms via the web-enabled app
Description: Group will receive reminders to enter new symptoms or changes in symptoms (based on a Likert scale or Y/N) on the following schedule: Week 1 (daily), Week 2 (every other day), Weeks 3-4 (once per week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Alerts
Description: Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Alerts
Description: Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
Study: NCT03322839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategies
Description: The school-management will participate in a one-day training aimed at providing knowledge and skills related the recommendations of the guideline for the prevention of common mental disorders at the workplace.In addition every intervention school will form an implementation team that is responsible for the implementation of the guideline. The implementation team will comprise of approximately 3-5 individuals with experience in the field of social and organizational work environment, for example school-management and occupational health and safety representative. The implementation teams will participate in 4-5 workshops aimed at supporting the implementation process. Intervention schools within the same municipality will participate in the same workshop in order to promote peer-support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single implementation strategy
Description: The school-management will participate in a one-day training aimed at providing knowledge and skills related to the recommendations of the guideline for the prevention of common mental disorders at the workplace
Study: NCT00607724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449
Study: NCT00999999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniotomy supra- or infratentorial, dural closure
Description: After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Craniotomy supra- or infratentorial, dural closure
Description: After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.
Study: NCT00852605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Non-Invasive Ventilation
Study: NCT01464775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Description: Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard White Light Laparoscopy
Description: Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
Study: NCT03551691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20mg Capsule
Description: Omeprazole 20mg daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Identically-appearing capsule to omeprazole for 28 days
Study: NCT03567629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg / m2, intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 days for a cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/m2 (two-week regimen) or 130mg/m2 (three week regimen), intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 or 21 days for a cycle.
Study: NCT02920112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone based Cognitive Behavioral Therapy
Description: 6 sessions of Telephone based Cognitive Behavioral Therapy over the telephone, lasting approximately 60 minutes each.
Study: NCT04224168

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Beans
Description: Please see arm group Green beans for description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid Pectin
Description: Please see arm group liquid pectin for description
Study: NCT00505310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing
Description: 20 minutes of writing on different topics at four different times.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing
Description: 20 minutes of writing on different topics at four different times.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
Study: NCT02775006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150mg/day
Study: NCT02764099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills Training
Description: The Life Skills Training (LST) program is a comprehensive competence enhancement prevention approach that teaches resistance skills while also emphasizing generic personal and social skills training. The LST program content and skills training is delivered to youth participants by trained providers through instruction, demonstration, behavioral rehearsal with feedback and social reinforcement, extended practice through homework assignments, and didactic teaching methods.
Study: NCT02758743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetium Lozenge
Description: Slow-release L-Cysteine to block smoke.derived acetaldehyde in saliva thereby inhibiting the formation of harmans

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with no active substance will not have the effect on intervention device.
Study: NCT00910286

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary Ventilator
Description: The aim of the present study was to compare two different cycling off modes in PSV, a fixed and other automatic, about ventilatory mechanic variables, breathing comfort and patient-ventilator asynchrony patterns
Study: NCT00903760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 20 mg/m\^2 by vein daily over 1-2 hours for 5 days for both Group 1 and Group 2. Group 1 receives decitabine on Days 1-5 of Cycles 1-3, 7-9, 13-15, and 19-21; and Group 2 is on Days 1-5 of every cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 20 mg/m\^2 by vein daily over 1-2 hours for 5 days for both Group 1 and Group 2. Group 1 receives decitabine on Days 1-5 of Cycles 1-3, 7-9, 13-15, and 19-21; and Group 2 is on Days 1-5 of every cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine 10 mg/m\^2 by vein daily over 1-2 hours for 5 days on Days 1-5 of Cycles 4-6, 10-12, 16-18, and 22-24.
Study: NCT01918592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI/acetate-PET imaging
Study: NCT04420039

Intervention type: DEVICE
Intervention: Endoscopic biliary transmural drainage
Description: Endosonography-guided biliodigestive anastomosis using a dedicated biliary lumen-apposing stent in order to proveide a biliary drainage in cases of palliative malignant biliary obstruction.~Two different strategies will be compared: single lumen-apposing stent vs lumen-apposing stent plus dousble-pigtail plastic stent.

Intervention type: DEVICE
Intervention: Endoscopic biliary transmural drainage
Description: Endosonography-guided biliodigestive anastomosis using a dedicated biliary lumen-apposing stent in order to proveide a biliary drainage in cases of palliative malignant biliary obstruction.~Two different strategies will be compared: single lumen-apposing stent vs lumen-apposing stent plus dousble-pigtail plastic stent.
Study: NCT01183390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg Tablets
Study: NCT03662269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indomethacin
Description: indomethacin (75mg, bid, po, 14days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (75mg, bid, po, 14days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: placebo (20mg, qd, po, 14days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole
Description: placebo (20mg, qd, po, 14days)
Study: NCT00463905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical assessment +/- radiography
Description: Clinical assessment: height loss, history of fracture, Margolis pain score, rib/pelvis distance
Study: NCT00000416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation counseling
Description: Provided in 2 in-person meetings and in follow-up phone calls

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation counseling
Description: Provided in 2 in-person meetings and in follow-up phone calls
Study: NCT03384303

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized meal test
Description: Preoperatively and postoperatively standardized meal test

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized meal test
Description: Preoperatively and postoperatively standardized meal test
Study: NCT03153150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acenocoumarol
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenindione
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Study: NCT01452568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 150mg/daily for three months, starting day after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin daily dosage to obtain an INR in between 2,0 to 3,0. Started the day after surgery and continued for three months.
Study: NCT01240551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F-18 NaF
Description: All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F-18 NaF
Description: All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.
Study: NCT02981927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical inactivity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Study: NCT02567851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Monoclonal antibody drug conjugate
Study: NCT00309647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine
Description: 2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine
Description: 2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine
Description: 2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine
Description: 2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Monovalent Whole virus (H5N1)
Description: 2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Monovalent Whole virus (H5N1)
Description: 2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Monovalent Whole virus (H5N1)
Description: 2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Monovalent Whole virus (H5N1)
Description: 2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
Study: NCT01638390

Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment with the VisuMax™ Femtosecond Laser
Description: The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
Study: NCT03863132

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAVR
Description: Repair of defective aortic valve by microsurgical Intervention.
Study: NCT00551850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-412
Description: oral solid dosage form administered three times weekly for 4 weeks (1 cycle)